Lionco(SH:603669) Zheng Quan Ri Bao·2025-10-11 05:18Core Viewpoint - Lingkang Pharmaceutical Group Co., Ltd. held its second extraordinary general meeting of shareholders on October 10, 2025, where the fifth board of directors was elected, and key management personnel were appointed [1][5]. Group 1: Board Composition - The fifth board of directors consists of 7 members: 3 non-independent directors, 3 independent directors, and 1 employee representative director [2][3]. - The board is chaired by Ms. Tao Lingping, with Mr. Tao Xiaogang, Mr. Zhang Hui as non-independent directors, and Mr. Wang Hongxin, Ms. Zhu Ming, and Ms. Du Juling as independent directors [2][3]. Group 2: Management Appointments - The company appointed Mr. Tao Xiaogang as the general manager, with Mr. Lü Jun, Mr. Liu Liming, and Mr. Sui Guoping as vice general managers [3][4]. - Mr. Zhang Junke was appointed as the financial director, Mr. Sui Guoping as the board secretary, and Mr. Liao Baoyu as the securities affairs representative [3][4]. Group 3: Committee Structure - The board has established four specialized committees: the Audit Committee, Nomination Committee, Compensation and Assessment Committee, and Strategic Committee, with independent directors holding a majority in the first three committees [3][4]. Group 4: Cancellation of Supervisory Board - The company decided to cancel the supervisory board, transferring its responsibilities to the Audit Committee of the board, in compliance with new regulations effective from July 1, 2024 [5][6]. Group 5: Shareholder Meeting Details - The extraordinary general meeting was legally convened, with all resolutions passed unanimously, including the election of the board and the cancellation of the supervisory board [11][17].